JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

Pharmaceuticals & Biotechnology

₹1160.90-20.30(-1.72%)

Market Closed as of Nov 6, 2025, 15:30 IST

Select time range

Valuation
Market Cap	18.82 kCr
Price/Earnings (Trailing)	39.17
Price/Sales (Trailing)	2.46
EV/EBITDA	16.26
Price/Free Cashflow	-392.89
MarketCap/EBT	27.6
Enterprise Value	20.79 kCr

Fundamentals
Revenue (TTM)	7.66 kCr
Rev. Growth (Yr)	11.4%
Earnings (TTM)	474.4 Cr
Earnings Growth (Yr)	17%

Profitability
Operating Margin	9%
EBT Margin	9%
Return on Equity	7.22%
Return on Assets	3.51%
Free Cashflow Yield	-0.25%

Price to Sales Ratio

Latest reported: 2

Revenue (Last 12 mths)

Latest reported: 8 kCr

Net Income (Last 12 mths)

Latest reported: 474 Cr

Growth & Returns
Price Change 1W	5.5%
Price Change 1M	5.5%
Price Change 6M	34.1%
Price Change 1Y	-5.7%
3Y Cumulative Return	45.2%
5Y Cumulative Return	17.5%
7Y Cumulative Return	7.1%
10Y Cumulative Return	11.4%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	487.7 Cr
Cash Flow from Operations (TTM)	1.07 kCr
Cash Flow from Financing (TTM)	-1.45 kCr
Cash & Equivalents	622.7 Cr
Free Cash Flow (TTM)	-43.5 Cr
Free Cash Flow/Share (TTM)	-2.73

Balance Sheet
Total Assets	13.52 kCr
Total Liabilities	6.95 kCr
Shareholder Equity	6.57 kCr
Current Assets	3.4 kCr
Current Liabilities	2.09 kCr
Net PPE	3.24 kCr
Inventory	1.23 kCr
Goodwill	2.65 kCr

Capital Structure & Leverage
Debt Ratio	0.19
Debt/Equity	0.4
Interest Coverage	2.29
Interest/Cashflow Ops	5.91

Dividend & Shareholder Returns
Dividend/Share (TTM)	5
Dividend Yield	0.42%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Pros

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Past Returns: Outperforming stock! In past three years, the stock has provided 45.2% return compared to 13.5% by NIFTY 50.

Momentum: Stock price has a strong positive momentum. Stock is up 5.5% in last 30 days.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: Market Cap wise it is among the top 20% companies of india.

Insider Trading: There's significant insider buying recently.

Cons

No major cons observed.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.42%
Dividend/Share (TTM)	5
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	30.16

Financial Health
Current Ratio	1.63
Debt/Equity	0.4

Technical Indicators
RSI (14d)	71.81
RSI (5d)	73.29
RSI (21d)	58.65
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Sell
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Summary of Latest Earnings Report from JUBILANT PHARMOVA

Summary of JUBILANT PHARMOVA's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Revenue Breakdown

Analysis of JUBILANT PHARMOVA's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.

Revenue

Last Updated: Jun 30, 2025

Description	Share	Value
Radiopharma	44.7%	868.6 Cr
Contract Development and Manufacturing Organisation- Sterile injectables	20.2%	392.6 Cr
Contract Research, Development and Manufacturing Organisation	16.0%	311.4 Cr
Allergy Immunotherapy	9.9%	191.4 Cr
Generics	8.5%	166 Cr
Unallocable Corporate	0.7%	12.8 Cr
Total		1.9 kCr

Share Holdings

Understand JUBILANT PHARMOVA ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
SPB TRUSTEE COMPANY PVT LTD	20.08%
HSB TRUSTEE COMPANY PVT LTD	19%
GOVERNMENT PENSION FUND GLOBAL	3.28%
REKHA JHUNJHUNWALA	3.28%
MILLER HOLDINGS PTE LTD	3.28%
MAV MANAGEMENT ADVISORS LLP	3.15%
EAST BRIDGE CAPITAL MASTER FUND I LTD	2.53%
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND	2.42%
QUANT MUTUAL FUND - QUANT SMALL CAP FUND	1.85%
THELEME INDIA MASTER FUND LIMITED	1.71%
Investor Education and Protection Fund Authority Ministry of Corporate Affairs	1.25%
ABAKKUS EMERGING OPPORTUNITIES FUND-1	1.15%
SBI LIFE INSURANCE CO. LTD	1.11%
KOTAK FUNDS - INDIA MIDCAP FUND	1%
NIKITA RESOURCES PRIVATE LIMITED	0.97%
PRIYAVRAT BHARTIA	0.88%
HARI SHANKER BHARTIA	0.23%
SHAMIT BHARTIA	0.08%
KAVITA BHARTIA	0.01%
TORINO OVERSEAS LIMITED	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is JUBILANT PHARMOVA Better than it's peers?

Detailed comparison of JUBILANT PHARMOVA against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.06 LCr	56.98 kCr	+3.80%	-6.40%	38.82	7.13	-	-
DIVISLAB	Divi's Lab	1.81 LCr	10.04 kCr	+16.20%	+15.50%	78.53	18.02	-	-
CIPLA	Cipla	1.21 LCr	29.39 kCr	-0.90%	+2.60%	22.31	4.13	-	-
DRREDDY	Dr. Reddy's Lab	1 LCr	34.79 kCr	-3.80%	-5.30%	21.39	2.88	-	-
AUROPHARMA	Aurobindo Pharma	66.85 kCr	33.03 kCr	+5.30%	-18.20%	19.53	2.02	-	-

Income Statement for JUBILANT PHARMOVA

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	981.2%	7,234	670	6,282	6,059	6,099	9,154
Other Income	854%	57	6.87	38	82	18	47
Total Income	978.4%	7,291	677	6,320	6,141	6,116	9,202
Cost of Materials	996.1%	1,985	182	1,666	1,349	1,349	3,119
Purchases of stock-in-trade	1187%	297	24	252	202	168	277
Employee Expense	925.8%	2,268	222	2,166	2,043	1,923	2,128
Finance costs	819.2%	240	27	188	145	184	287
Depreciation and Amortization	894.6%	369	38	554	382	349	462
Other expenses	924.3%	1,476	145	1,462	1,442	1,243	1,939
Total Expenses	934%	6,670	646	6,248	5,501	5,235	7,957
Profit Before exceptional items and Tax	1903.2%	622	32	72	640	881	1,245
Exceptional items before tax	2106.7%	360	-16.89	-56.82	0	-21.23	-34.64
Total profit before tax	6900%	981	15	16	640	860	1,211
Current tax	1015.8%	213	20	181	173	270	323
Deferred tax	-508.9%	-68.9	-10.48	-88.42	45	27	-10.53
Total tax	1528.7%	144	9.78	93	217	297	312
Total profit (loss) for period	13217.4%	836	7.27	-64.88	413	836	898
Other comp. income net of taxes	1791.9%	85	5.44	220	244	174	33
Total Comprehensive Income	7566.7%	921	13	156	657	1,010	931
Earnings Per Share, Basic	1243.4%	52.99	4.87	-3.83	26	52.48	56.39
Earnings Per Share, Diluted	1243.3%	52.85	4.86	-3.83	26	52.48	56.39
Debt equity ratio	-	-	-	-	-	0	-
Debt service coverage ratio	-	-	-	-	-	0	-
Interest service coverage ratio	-	-	-	-	-	0	-

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	3.4%	1,966	1,901	1,929	1,822	1,752	1,732
Other Income	-20%	9.8	12	12	9.2	22	14
Total Income	3.3%	1,976	1,913	1,941	1,831	1,774	1,746
Cost of Materials	8.7%	565	520	584	467	469	465
Purchases of stock-in-trade	1.4%	74	73	85	81	69	62
Employee Expense	7.6%	636	591	591	560	564	553
Finance costs	2.1%	50	49	53	56	61	71
Depreciation and Amortization	7.2%	105	98	95	91	91	91
Other expenses	-2.5%	392	402	367	400	344	366
Total Expenses	1.3%	1,780	1,758	1,731	1,681	1,615	1,642
Profit Before exceptional items and Tax	27.5%	196	154	209	150	159	104
Exceptional items before tax	-	-5.8	0	-3.3	-18.9	-14.2	396
Total profit before tax	23.5%	190	154	206	131	144	500
Current tax	-5.4%	36	38	115	32	40	26
Deferred tax	153.8%	34	14	-60.1	-2.5	1.9	-8.2
Total tax	35.3%	70	52	55	30	42	18
Total profit (loss) for period	17.8%	120	102	151	101	102	482
Other comp. income net of taxes	297.5%	160	41	-4.6	64	30	-3.9
Total Comprehensive Income	95.1%	280	144	147	164	132	478
Earnings Per Share, Basic	20%	7.59	6.49	9.71	6.37	6.47	30.44
Earnings Per Share, Diluted	20.1%	7.57	6.47	9.68	6.36	6.46	30.35

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	-5%	746	785	810	88	2,710	3,140
Other Income	-2.9%	100	103	138	126	48	173
Total Income	-4.8%	845	888	948	214	2,757	3,313
Cost of Materials	-9.1%	282	310	396	0	1,329	1,683
Purchases of stock-in-trade	-118.2%	0	6.5	15	0	66	109
Employee Expense	6.9%	203	190	167	49	221	265
Finance costs	0%	30	30	19	31	102	136
Depreciation and Amortization	10.6%	53	48	43	6.25	100	107
Other expenses	5.4%	235	223	225	45	611	820
Total Expenses	-5.9%	796	846	869	131	2,484	3,013
Profit Before exceptional items and Tax	17.1%	49	42	79	82	273	301
Exceptional items before tax	-	-11.2	0	0	0	0	-1.7
Total profit before tax	-9.8%	38	42	79	82	273	299
Current tax	227.6%	20	6.8	14	14	45	26
Deferred tax	-204.3%	-1.4	3.3	16	-9.91	13	-48.43
Total tax	88.9%	18	10	29	3.75	59	-22.3
Total profit (loss) for period	-41.9%	19	32	50	78	214	321
Other comp. income net of taxes	13.3%	-0.3	-0.5	1.32	0.02	-1.75	-1.88
Total Comprehensive Income	-40%	19	31	51	79	213	319
Earnings Per Share, Basic	-78.8%	1.21	1.99	3.13	4.93	13.47	20.16
Earnings Per Share, Diluted	-78.8%	1.21	1.99	3.13	4.93	13.47	20.16
Debt equity ratio	-	-	-	-	-	0	-
Debt service coverage ratio	-	-	-	-	-	0	-
Interest service coverage ratio	-	-	-	-	-	0	-

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	10.2%	66	60	217	196	166	167
Other Income	33.3%	0.8	0.7	18	18	44	20
Total Income	11.9%	67	60	235	214	210	186
Cost of Materials	-	0	0	78	77	62	66
Purchases of stock-in-trade	-	0	0	0	0	0	0
Employee Expense	18.2%	27	23	51	52	51	49
Finance costs	-25%	2.5	3	7	7.4	7.8	7.6
Depreciation and Amortization	20%	1.6	1.5	13	13	13	13
Other expenses	8%	28	26	60	57	62	56
Total Expenses	9.4%	59	54	212	206	193	186
Profit Before exceptional items and Tax	36.4%	8.5	6.5	24	8.7	17	0
Exceptional items before tax	-	0	0	0	0	0	-11.2
Total profit before tax	36.4%	8.5	6.5	24	8.7	17	-11.2
Current tax	100%	1.4	1.2	8.2	6.3	5.3	0
Deferred tax	26900%	55	1.2	1.7	-2.9	0.8	-1
Total tax	3828.6%	56	2.4	9.9	3.4	6.1	-1
Total profit (loss) for period	-254.2%	-6.4	5.8	14	5.3	10	-10.2
Other comp. income net of taxes	-63.6%	-0.8	-0.1	0.3	-0.2	-0.2	-0.2
Total Comprehensive Income	-274.5%	-7.2	5.7	14	5.1	10	-10.4
Earnings Per Share, Basic	-118.8%	-0.4	0.36	0.86	0.33	0.66	-0.64
Earnings Per Share, Diluted	-118.8%	-0.4	0.36	0.86	0.33	0.66	-0.64

Balance Sheet for JUBILANT PHARMOVA

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-42.8%	623	1,088	1,077	96	974	1,014
Loans, current	1200%	2.3	1.1	1.2	0.08	1	1.14
Total current financial assets	-17.2%	1,773	2,142	2,085	212	2,002	2,106
Inventories	8.8%	1,228	1,129	1,162	129	1,328	1,381
Current tax assets	476.5%	99	18	37	1.67	24	12
Total current assets	-3.2%	3,397	3,510	3,502	363	3,606	3,762
Property, plant and equipment	52.1%	3,242	2,132	2,128	216	2,250	2,298
Capital work-in-progress	-13.7%	2,344	2,715	1,857	125	1,095	773
Investment property	-	0	0	0	0	0	-
Goodwill	4.3%	2,649	2,541	2,480	246	2,452	2,429
Non-current investments	2.9%	37	36	34	3.44	33	33
Loans, non-current	0%	0.3	0.3	0.3	0.03	0.4	0.43
Total non-current financial assets	4.8%	66	63	56	5.45	54	52
Total non-current assets	9.6%	10,062	9,179	8,423	767	7,793	7,394
Total assets	6%	13,521	12,756	11,924	1,155	11,400	11,157
Borrowings, non-current	7.9%	2,319	2,150	2,542	317	3,170	3,110
Total non-current financial liabilities	11.4%	3,258	2,924	2,878	338	3,392	3,325
Provisions, non-current	11.9%	133	119	102	10	93	92
Total non-current liabilities	11.7%	4,861	4,353	4,051	424	4,208	3,992
Borrowings, current	-2.4%	280	287	283	25	250	300
Total current financial liabilities	-10.6%	1,668	1,866	1,704	162	1,589	1,510
Provisions, current	2.6%	80	78	65	6.64	73	78
Current tax liabilities	17.6%	21	18	7.7	3.7	11	62
Total current liabilities	-3.6%	2,088	2,165	1,947	189	1,790	1,772
Total liabilities	6.6%	6,950	6,518	5,997	613	5,998	5,765
Equity share capital	0%	16	16	16	1.58	16	16
Non controlling interest	-20.2%	-19.8	-16.3	-13.5	-1.28	-8.7	-7.49
Total equity	5.3%	6,572	6,239	5,927	542	5,401	5,392
Total equity and liabilities	6%	13,521	12,756	11,924	1,155	11,400	11,157

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-8.3%	12	13	20	36	11	11
Loans, current	-12.5%	0.1	0.2	0.2	0.1	0.1	0.02
Total current financial assets	-83.6%	37	220	151	240	226	213
Inventories	-100.4%	0	232	255	251	276	314
Total current assets	-88.8%	55	484	451	541	565	579
Property, plant and equipment	-81.3%	97	515	522	523	493	491
Capital work-in-progress	-82.2%	4.2	19	26	37	59	47
Goodwill	-100.7%	0	137	137	137	137	137
Non-current investments	31.1%	2,172	1,657	1,657	1,657	1,657	1,657
Loans, non-current	-25%	0	0.2	0.2	0.2	0.3	0.3
Total non-current financial assets	30.7%	2,180	1,668	1,669	1,668	1,668	1,666
Total non-current assets	-4.3%	2,321	2,425	2,441	2,451	2,449	2,430
Total assets	-18.4%	2,376	2,910	2,892	2,992	3,014	3,008
Borrowings, non-current	-78.9%	50	233	244	246	250	174
Total non-current financial liabilities	-80.2%	51	254	267	247	282	209
Provisions, non-current	-68.5%	9.5	28	27	27	24	23
Total non-current liabilities	-76.8%	66	281	295	302	306	233
Borrowings, current	-101.4%	0	73	78	96	123	128
Total current financial liabilities	-86.9%	36	268	249	282	327	330
Provisions, current	-52.1%	4.5	8.3	6.8	6.9	10	11
Current tax liabilities	0%	13	13	0.2	0.2	0.2	0.16
Total current liabilities	-79.3%	65	310	298	315	368	361
Total liabilities	-77.8%	132	592	593	617	674	594
Equity share capital	0%	16	16	16	16	16	16
Total equity	-3.2%	2,244	2,318	2,299	2,374	2,340	2,415
Total equity and liabilities	-18.4%	2,376	2,910	2,892	2,992	3,014	3,008

Cash Flow for JUBILANT PHARMOVA

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	819.2%	240	27	188	145	-	-
Change in inventories	853%	78	9.08	-64.68	-95.65	-	-
Depreciation	894.6%	369	38	554	382	-	-
Unrealised forex losses/gains	-4.7%	0.1	0.14	-5.35	40	-	-
Adjustments for interest income	2136%	37	2.61	9.83	2.45	-	-
Share-based payments	2300%	4.3	0.85	3.65	1.12	-	-
Net Cashflows from Operations	1018.8%	1,310	118	865	1,032	-	-
Income taxes paid (refund)	1085%	238	21	204	194	-	-
Net Cashflows From Operating Activities	1015.6%	1,072	97	661	838	-	-
Cash receipts from share of profits of partnership firm or association of persons or LLP	-	0	0	8.82	0	-	-
Proceeds from sales of PPE	13433.3%	5	0.97	19	3.52	-	-
Purchase of property, plant and equipment	1152.8%	1,116	90	814	600	-	-
Proceeds from sales of investment property	-	0	0	0	44	-	-
Purchase of investment property	-	0	0	0	2.32	-	-
Proceeds from government grants	2668.2%	610	23	244	0	-	-
Interest received	2256.7%	38	2.57	9.98	4.02	-	-
Other inflows (outflows) of cash	-178.3%	-0.3	2.66	-0.14	170	-	-
Net Cashflows From Investing Activities	888.2%	488	-60.79	-544.41	-380.37	-	-
Payments to acquire or redeem entity's shares	-	5.6	0	0	0	-	-
Proceeds from exercise of stock options	-	0.9	0	0	0	-	-
Proceeds from borrowings	136.4%	27	12	3,005	247	-	-
Repayments of borrowings	8353.8%	1,100	14	2,773	5	-	-
Payments of lease liabilities	1052.3%	60	6.12	70	60	-	-
Dividends paid	1031.8%	80	7.98	80	80	-	-
Interest paid	921.7%	236	24	234	135	-	-
Other inflows (outflows) of cash	73.3%	0	-2.74	-3.97	0	-	-
Net Cashflows from Financing Activities	-3185.2%	-1,452.7	-43.25	-156.69	-32.6	-	-
Effect of exchange rate on cash eq.	14900%	25	1.16	71	57	-	-
Net change in cash and cash eq.	2040.7%	132	-5.75	30	482	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	0%	30	30	19	31	-	-
Change in inventories	-80.6%	13	63	9.58	0	-	-
Depreciation	10.6%	53	48	43	6.25	-	-
Unrealised forex losses/gains	1050%	3.3	1.2	0.44	0.01	-	-
Dividend income	-43.8%	19	33	97	97	-	-
Adjustments for interest income	180%	1.4	0.5	0.53	0.86	-	-
Share-based payments	57.1%	2.1	1.7	0.97	0.5	-	-
Net Cashflows from Operations	-3.9%	148	154	-47.67	13	-	-
Income taxes paid (refund)	0%	12	12	17	19	-	-
Other inflows (outflows) of cash	-	0	1	0	0	-	-
Net Cashflows From Operating Activities	-4.9%	136	143	-65.12	-6.47	-	-
Cashflows used in obtaining control of subsidiaries	-	0	0	8.75	0	-	-
Proceeds from sales of PPE	-	0	0	0.92	0.04	-	-
Purchase of property, plant and equipment	-70.1%	21	68	60	1.95	-	-
Proceeds from sales of investment property	-500%	0.4	0.9	0	0	-	-
Cash receipts from repayment of advances and loans made to other parties	-	0	0	0.05	0	-	-
Dividends received	-43.8%	19	33	97	97	-	-
Interest received	157.1%	1.4	0.3	0.58	0.87	-	-
Other inflows (outflows) of cash	-18.2%	-0.3	-0.1	-0.12	0	-	-
Net Cashflows From Investing Activities	92%	-2.3	-40.3	31	96	-	-
Proceeds from borrowings	-101%	0	100	128	6	-	-
Repayments of borrowings	9.1%	37	34	0	0	-	-
Payments of lease liabilities	7.1%	10	9.4	6.76	2.93	-	-
Dividends paid	0%	80	80	80	80	-	-
Interest paid	0%	30	30	18	30	-	-
Other inflows (outflows) of cash	96.2%	0	-25	0	0	-	-
Net Cashflows from Financing Activities	-100.3%	-156.8	-77.8	23	-107.37	-	-
Net change in cash and cash eq.	-202.1%	-23.5	25	-11.54	-17.82	-	-

What does JUBILANT PHARMOVA LIMITED do?

Pharmaceuticals•Healthcare•Small Cap

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:5,399

Website:www.jubilantpharmova.com

JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does JUBILANT PHARMOVA LIMITED do?